Applications of 2-Bromopyrimidine in Industrial Manufacturing

As an established chemical raw material supplier, we provide high-purity 2-Bromopyrimidine to international industrial manufacturers seeking reproducible quality and proven integration into advanced chemical syntheses. Below, we outline its principal downstream application scenarios, each documented with current compliance standards, formulation use levels, manufacturing process steps, and representative finished products.

1. Pharmaceutical Intermediate for Antiviral Drug Synthesis

Many pharmaceutical companies use 2-Bromopyrimidine as a key building block during the heterocycle modification steps in nucleoside analogue APIs, especially anti-hepatitis B and anti-HIV drugs. The compound enables the introduction of pyrimidine functionality during the early stage of multi-step synthesis for intermediates that undergo further substitution, coupling, or condensation reactions. Accurate ratio control during the alkylation or Suzuki coupling reactions is essential to achieve pharmacopoeia-grade intermediate purity, requiring consistent specification validation and residue control throughout scale-up.

Industry compliance standards

• ICH Q7 (Good Manufacturing Practice for Active Pharmaceutical Ingredients)
• EU GMP (EudraLex Volume 4 Part II)
• Current editions of USP, EP, JP (for relevant API intermediates)
• FDA 21 CFR Part 211 (for US-bound drug manufacturing)

Typical usage ratio

• Usually 0.8–1.3 equivalents per target molecule in single-step substitutions; precise ratio determined by substrate reactivity and downstream API yield requirements

Downstream process integration

• Added directly to reaction vessels for halogen exchange, Suzuki coupling, or Buchwald–Hartwig amination, typically at the step where the pyrimidine core is introduced to the protected nucleoside skeleton; followed by further derivatization or hydrolysis

Final product types

• API intermediates such as brominated nucleoside analogues
• Final pharmaceutical actives for anti-hepatitis B and anti-HIV medications

2. Agrochemical Intermediate for Fungicide Synthesis

Agrochemical manufacturers integrate this compound for constructing pyrimidine-containing cores in modern systemic fungicides, especially for the formulation of broad-spectrum products targeting fungal pathogens in cereal, vegetable, and fruit crops. The compound typically enters the synthetic route as the halogen source in C-C or C-N coupling reactions. Rigorous process validation and impurity profile control are needed, aligning with agrochemical registration dossier requirements throughout pilot and commercial scale runs.

Industry compliance standards

• FAO/WHO Specification on Technical Grade Active Ingredients
• REACH Regulation (EC) No 1907/2006 (for European producers)
• ISO 9001:2015 Quality Management (for certified suppliers)
• OECD Good Laboratory Practice Principles

Typical usage ratio

• 0.4–1.1 molar equivalents per active ingredient intermediate, with ratio adjusted according to the reactivity and conversion yield of the specific crop protection molecule design

Downstream process integration

• Charged into batch synthesis for C-N or C-C bond formation via palladium-catalyzed cross coupling, serving as a core intermediate for further methylation or sulfonation steps before formulation into technical concentrate

Final product types

• Systemic fungicidal actives such as pyrimethanil derivatives
• Formulated crop protection agents (EC, SC, WG forms)

3. Chemical Intermediate for Electronic Material Synthesis

Manufacturers of specialty materials for organic light-emitting diode (OLED) displays and advanced electronic components employ this compound to construct N-heterocyclic structures in high-purity intermediates required for electronic-grade polymers or organic semiconductors. The strictest process and trace residue control is enforced due to the high sensitivity of electronic applications to halogen and trace organic contamination—necessitating continuous batch monitoring and post-synthesis purification tailored to downstream device requirements.

Industry compliance standards

• IEC 61249-2-21 Halogen-Free Standards (for circuit and component materials)
• JEITA EM-3609 (Japan Electronics and Information Technology Industries Association)
• ISO 9001:2015 (for advanced material manufacturing)
• RoHS Directive 2011/65/EU (for electronics placed on EU market)

Typical usage ratio

• 0.6–1.0 equivalents based on the polymer chain length and desired level of nitrogen incorporation; fine-tuned for end-use conductivity or emission optimization

Downstream process integration

• Utilized in the early build-up phase for N-doped aromatic polymerization or as a coupling substrate in aromatic substitution steps; followed by multi-stage purification and extended drying to electronic-grade standards

Final product types

• OLED emitter layers
• N-heterocyclic conducting polymers
• Electronic-grade intermediate precursors

4. Intermediate for Pharmaceutical API: Oncology Segment

Within sterile oncology drug formulation, several modern kinase inhibitor APIs require bromopyrimidine derivatives as essential intermediates. These compounds undergo further transformations, such as borylation or direct arylation, to furnish advanced intermediates for next-generation small molecule anti-cancer agents. The highly regulated environment mandates full traceability, with source information, in-process QC, and continuous batch consistency documentation in line with global pharmacopoeial and GMP expectations.

Industry compliance standards

• US FDA DMF (Drug Master File) Type II listing for API intermediates
• Chinese Pharmacopoeia (ChP 2020 Edition) for oncology actives
• PIC/S GMP Guide PE009
• EMA Guideline on the Formalized Risk Assessment for Excipients

Typical usage ratio

• 1.0–1.2 equivalents per target kinase inhibitor core intermediate, with adjustment based on the required substitution level and the removal efficiency of by-products post-coupling

Downstream process integration

• Introduced into the main reactor at the aryl or heteroaryl coupling stage, preceding isolating/protection steps for secondary transformation into API final form; all processing executed in cGMP suites with validated solvent systems

Final product types

• Advanced intermediates for kinase inhibitor APIs (e.g., pyrimidine-derived anti-cancer drugs)
• Oncology API compounds supplied in injectable or oral dosage forms

5. Synthesis of Specialty Dyes for Analytical Chemistry

Leading manufacturers of analytical dyes and labeling reagents rely on this raw material to synthesize pyrimidine-based chromophores for LC, GC, and immunodiagnostics kits. Its bromo group facilitates Suzuki or Stille coupling reactions, allowing for precise introduction of aromatic substituents that fine-tune detection sensitivity. Production necessities include verification of residual halide content and maintenance of color reproducibility over large-scale runs, as detailed by analytical reagent industry specifications.

Industry compliance standards

• ISO 17034:2016 (General requirements for the competence of reference material producers)
• Analytical grade requirements according to ACS Reagent Chemical Standards
• EN ISO/IEC 17025:2017 (Testing and calibration laboratories quality standard)
• REACH Annex VII–X (for raw material traceability in EU)

Typical usage ratio

• 0.9–1.1 equivalents, precisely measured to match stoichiometric demands of the target dye backbone, controlling for batch-to-batch color uniformity

Downstream process integration

• Charged prior to coupling or condensation reaction, with in-line UV-vis monitoring and chromatographic verification for dye purity; subsequent steps include purification under reduced pressure and drying to analytical specification

Final product types

• Chromatographic labeling agents
• Pyrimidine-based analytical dyes
• Calibrant reference standards for detection kits